Position in ADCT
as of Mar 31, 2026
· filed May 12, 2026
Position Value
$296,377
-$103,384 QoQ
Shares Held
79,034
-30.2% QoQ
Ownership
0.062%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
5 quarters on record
Voting authority
Sole 3%
Shared 0%
None 97%
Common Shares in ADCT Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Mar 31, 2026Creative Planning holds $105,843,094 across 40 Drug Manufacturers - Specialty & Generic names. ADCT ranks #30 (0.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RDY |
Dr Reddys Laboratories Ltd
|
1,167,182 | $16,165,470 | |
| 2 | UTHR |
UNITED THERAPEUTICS Corp
|
22,075 | $13,090,033 | |
| 3 | VTRS |
Viatris Inc
|
770,971 | $10,415,817 | |
| 4 | TAK |
Takeda Pharmaceutical Co Ltd
|
542,996 | $10,056,285 | |
| 5 | ZTS |
Zoetis Inc.
|
77,690 | $9,183,734 | |
| 6 | NBIX |
Neurocrine Biosciences Inc
|
68,387 | $9,009,303 | |
| 7 | HLN |
Haleon plc
|
630,997 | $6,316,279 | |
| 8 | LNTH |
Lantheus Holdings, Inc.
|
80,292 | $6,090,147 |
All Filings in ADCT
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $296,377 | 79,034 | Shares | Sole | 2026-05-12 | |
| 2025-12-31 | $399,761 | 113,247 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $426,604 | 106,651 | Shares | Defined | 2025-11-14 | |
| 2025-06-30 | $96,477 | 35,999 | Shares | Defined | 2025-08-08 | |
| 2024-12-31 | $945 | 475 | Shares | Defined | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||